Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312194 | 0.89 | GAA (0.41) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14312308 | 0.86 | POLB (0.36) | GAASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL14312176 | 0.86 | POLB (0.33) | SMN1; SMN2HTTPOLB | |
| SCHEMBL14312207 | 0.85 | GAA (0.43) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14312144 | 0.84 | GAA (0.50) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14312267 | 0.84 | GAA (0.50) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14312193 | 0.81 | POLB (0.33) | SMN1; SMN2HTTPOLB | |
| SCHEMBL14236884 | 0.80 | GAA (0.42) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14236949 | 0.80 | GAA (0.42) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14312280 | 0.73 | POLB (0.34) | SMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987383-B2 | Triazine derivatives and application thereof | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130023629-A1 | TRIAZINE DERIVATIVES AND APPLICATION THEREOF | SHINRYO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2537833-A1 | TRIAZINE DERIVATIVE, AND APPLICATION THEREOF | Nippon Kasei Chemical Company Limited (JP) | 2012-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023629-A1 | TRIAZINE DERIVATIVES AND APPLICATION THEREOF | HSPH1, PRDX3, PRXL2A | GAA 2987/4885LMNA 4443/4885MAPT 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.